NONOF:OTO-Novo-Nordisk A/S (USD)

COMMON STOCK | Biotechnology | OTC Pink

Last Closing

USD 124.02

Change

+0.06 (+0.05)%

Market Cap

USD 84.43B

Volume

1.93K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Novo Nordisk A/S is a healthcare company that is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company has two business segments: diabetes & obesity care and biopharmaceuticals.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-15 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
CMXHF CSL Limited

N/A

USD 89.03B
CSLLY CSL Ltd

N/A

USD 84.45B
UCBJF UCB SA

N/A

USD 25.40B
UCBJY UCB SA ADR

N/A

USD 24.49B
ARGNF argenx SE

N/A

USD 22.81B
GNMSF Genmab A/S

N/A

USD 18.12B
WXIBF WuXi Biologics

N/A

USD 7.17B
WXXWY WuXi Biologics (Cayman) Inc

N/A

USD 7.17B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 6.76B
SBMFF Sino Biopharmaceutical Limited

N/A

USD 5.92B

ETFs Containing NONOF

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 21.00% 73% C 77% C+
Dividend Return 0.91% 100% F 24% F
Total Return 21.90% 73% C 78% C+
Trailing 12 Months  
Capital Gain 44.90% 88% B+ 88% B+
Dividend Return 1.60% 62% D 19% F
Total Return 46.50% 88% B+ 87% B+
Trailing 5 Years  
Capital Gain 402.61% 94% A 96% N/A
Dividend Return 30.90% 91% A- 84% B
Total Return 433.51% 94% A 96% N/A
Average Annual (5 Year Horizon)  
Capital Gain 38.79% 69% C- 74% C
Dividend Return 42.53% 69% C- 73% C
Total Return 3.74% 95% A 63% D
Risk Return Profile  
Volatility (Standard Deviation) 23.31% 94% A 82% B
Risk Adjusted Return 182.46% 100% F 100% F
Market Capitalization 84.43B 100% F 100% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.